Background: Health careeassociated infection (HAI) rates have fallen with the development of multifaceted infection prevention programs. These programs require ongoing investments, however. Our objective was to examine the cost-effectiveness of hospitals' ongoing investments in HAI prevention in intensive care units (ICUs). Methods: Five years of Medicare data were combined with HAI rates and cost and quality of life estimates drawn from the literature. Life-years (LYs), quality-adjusted LYs (QALYs), and health care expenditures with and without central lineeassociated bloodstream infection (CLABSI) and/or ventilator-associated pneumonia (VAP), as well as incremental cost-effectiveness ratios (ICERs) of multifaceted HAI prevention programs, were modeled. Results: Total LYs and QALYs gained per ICU due to infection prevention programs were 15.55 LY and 9.61 QALY for CLABSI and 10.84 LY and 6.55 QALY for VAP. Reductions in index admission ICU costs were $174,713.09 for CLABSI and $163,090.54 for VAP. The ICERs were $14,250.74 per LY gained and $23,277.86 per QALY gained. Conclusions: Multifaceted HAI prevention programs are cost-effective. Our results underscore the importance of maintaining ongoing investments in HAI prevention. The welfare benefits implied by the advantageous ICERs would be lost if the investments were suspended.
The estimated overall direct annual cost of HAIs ranges from $28 to $45 billion, and health careeassociated sepsis and pneumonia are among the most costly in terms of mortality as well as financially. 2 In a study of patients who underwent invasive surgery, the attributable mean length of stay was 10.9 days, costs were $32,900, and mortality was 19.5% for each case of hospitalacquired sepsis; the corresponding values for hospital-acquired pneumonia were 14.0 days, $46,400, and 11.4%. 3 The majority of these infections are associated with external devices inserted in intensive care units (ICU), namely central line catheters and ventilators. 4 Various evidence-based clinical interventions, including bundles and guidelines, have been published in an effort to decrease HAIs in the ICU. [5] [6] [7] Effective implementation of these interventions is crucial to support clinician adherence at the bedside and reduce HAI rates. [8] [9] [10] Indeed, focusing on improving the organizational culture by promoting standardized evidence-based practice protocols and providing clinician compliance audit and feedback loops, expert-led educational sessions, and forums for dissemination are often needed to improve clinician adherence and patient safety. Such interventions are most often accomplished in hospitals by investing in multifaceted infection prevention programs. 7, 11 As a result of past investments, the United States has seen vast improvements in many HAI rates, with impressive progress toward the 5-year targets set out in the HAI Action Plan. 12 However, focusing on infection prevention uses limited and competing resources and requires an ongoing financial commitment by the institution. In addition, the foregoing cost and resource utilization estimates are limited to those directly incurred by the institution during the hospitalization in which the infection occurred. The societal welfare benefits of improved HAI prevention in the hospital include not only the immediate health benefits and cost reductions of infection prevention, but also the long-term benefits of improved survival and the value of future health care expenditures. Furthermore, these long-term posthospitalization costs are important to those needing a societal perspective, such as the Centers for Medicaid and Medicare Services (CMS), other insures, and those implementing accountable care organizations. Cost-effectiveness modeling can guide public policy and institutional investment decisions by quantifying the long-term health and economic consequences attributable to different strategies, and help clarify the full impact of the infections, as well as the value of past and future investments in reducing infections. Using a societal perspective, the present study aimed to examine the costeffectiveness of a hospital's ongoing investment in preventing HAIs in an ICU. To do so, we developed a model that estimates the attributable long-term patient outcomes and health care expenditures associated with a multifaceted infection prevention program designed to decrease the rates of central lineeassociated bloodstream infection (CLABSI) and ventilator-associated pneumonia (VAP). The comparator was usual care without an ongoing investment in an infection prevention program.
METHODS

Long-term cost-effectiveness HAI prevention policy model
We developed a long-term HAI cost-effectiveness policy model that starts with an index hospitalization during which an elderly subject has an ICU stay. Each subject's experience during the index ICU stay was characterized, including the probability of developing a CLABSI or VAP, the conditional probability of inpatient death due to the specific HAI type, and the incremental hospital costs associated with each infection. We modeled 5-year postdischarge experiences using a 6-state (ie, living in community, using home health care, living in a nursing home, inpatient hospital, emergency room visit, and dead) discrete-time dynamic model to estimate postdischarge survival, quality of life, and health care costs, each of which were conditional on having or not having experienced an HAI during the index ICU stay (Fig 1) . We examined alternative assumptions about the lasting consequences of infections. The time horizon for the model was lifetime, and we calculated incremental cost-effectiveness ratios (ICERs) both as costs per life year (LY) and as costs per quality-adjusted LY (QALY). Because the intervention is applied at the unit level, we present ICERs at the unit level.
The ICU was chosen as the setting for this study because critically ill patients are at the greatest risk for infection, surveillance data regarding infections are readily available from ICUs, and evidence of efficacy of infection prevention programs exist and are the focus of national targets. The choice of elderly subjects is relevant, because the majority of ICU patients are elderly, and also pragmatic, because it allowed us to use Medicare data for long-term follow-up. The 6 health states were chosen because they reflect meaningful differences in quality of life and associated health care utilization.
Data
Base case model parameters were drawn from the literature (Table 1) or estimated from 2 unique datasets compiled by the research team. The first dataset was a cohort of 17,537 elderly Medicare patients admitted to 31 hospitals during 2002 with clinical data on HAI outcomes from infection surveillance conducted by infection preventionists and submitted to the Centers for Disease Control and Prevention's (CDC) National Nosocomial Infection Surveillance (NNIS) system. These data were augmented with 5 years of Medicare claims data that allowed us to assess the long-term health outcomes and health care utilization attributable to HAIs. 13 The second dataset was from a recent National
Healthcare Safety Network (NHSN) research group in which 701 hospitals provided ICU-specific device utilization and HAI rates for 2011. 14 Other parameters required to determine the health benefits and economic costs included estimates of the deaths attributable to HAI and estimates of the incremental index hospital costs attributed to HAI, which were derived from the literature 3 and life tables. 15 
Infection prevention costs
The cost of a multifaceted infection prevention program was based on published estimates from the Michigan Keystone ICU Patient Safety Program. 16 The in-depth costing analysis was based on a stratified random sample of 6 Michigan hospitals participating in that program. We chose these cost estimates because the infection prevention program focused on decreasing rates of CLABSI and VAP in ICUs. Using an in-depth activity-based costing approach in the 6 hospitals, we estimated the average cost of an annualized infection prevention program as $161,000 per year per hospital, including both startup ($16,000) and ongoing implementation ($145,000) costs. Because we were interested in the ongoing investment, we used the $145,000 ongoing implementation costs in our base case analysis.
Comparator and postintervention HAI rates
The usual care comparator-associated HAI rates and device-days for CLABSI and VAP came from 2004 published NNIS data, 17 and the postintervention ICU HAI rates were drawn from 2011 NHSN published data. 18 These HAI rates represent a 76% reduction in CLABSI and a 77.6% reduction in VAP, similar to rates found in previous clinical trials assessing the effectiveness of multifaceted infection prevention programs.
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Postdischarge health states, quality of life, and costs
Medicare data were used to estimate the monthly conditional probabilities of the health states for those who had experienced an HAI and those who had not experienced an HAI. These 5-year (60-month) postindex ICU stay estimates were developed to characterize health status and associated resource utilization as a function of HAI while controlling for demographic characteristics (ie, age, sex, and race), chronic comorbidities (for which we used 30 aggregated condition codes and 184 hierarchical condition codes using DxCG software), [20] [21] [22] and dual eligibility for Medicare and Medicaid. 13 We extended the survival functions to the end of life by applying agespecific mortality rates using life tables. 15 Because impending death has substantial effects on health status, we enhanced the models by conditioning on the time until death and used alternative assumptions about the lasting consequences of infections to extend the utilization predictions through the end of life. Quality of life adjustments were based on similar health states described in the literature. To find these quality of life adjustments, we searched the Cost-Effectiveness Analysis Registry database. 23 From these quality of life adjustments, disutilities were calculated based on the estimated number of days in each health state. To account for the effects of aging on quality of life, we included an age-specific QALY assuming 0.80 at age 65 years and included an annual decrement of 0.005 for each year thereafter. We also present the results in LY gained without the quality adjustment.
Average cost estimates obtained from published literature were assigned for the utilization of the following resources: hospital day, homecare day, emergency room day, and long-term care day. We accumulated the costs of utilization and generated the net present value of postdischarge health care costs at the time of index ICU admission. A 3% discount rate was applied to costs and health benefits. 24 All survival models were analyzed using Stata Version 12 (StataCorp, College Station, TX). The final cost-effectiveness models were developed in Excel (Microsoft, Redmond, WA). All cost data are presented in 2013 US dollars. To determine the robustness of the results, we conducted 1-way sensitivity analyses testing the assumptions of the intervention effectiveness, underlying devicedays in the ICU, attributable mortality, intervention costs, downstream utilization costs, discount rates, and utilities used in the QALYs. We also examined the robustness of the results in a less heterogeneous population and varied the age cohorts limiting the analysis to those aged 65-69 years and those aged 75-79 years. The consolidated health economic evaluation reporting standards were followed in developing this report. 25 Institutional Review Board approval was obtained from Columbia University Medical Center and RAND Corporation. Table 2 provides sample characteristics for the sample of elderly ICU patients that form the basis of our model estimates by sample cohort, including all elderly patients in the sample, those that experienced a CLABSI, those that experienced a VAP, and 2 agespecific cohorts used in sensitivity analyses. The mean age of the sample was 77.1 years old, 49% were female, and 91% were white.
RESULTS
Only 13% of the sample had dual eligibility for Medicare and Medicaid, and the average number of aggregated condition codes was 4.83. More than one-half of the sample (57%) died during the 5-year follow-up period. Table 3 presents the model base case results for the average ICU. Starting with the estimated number of infections and deaths averted for both CLABSI and VAP per ICU, we estimated the total number of LY gained (ie, increased LY of 15.55 and 10.84 from reduced risk of CLABSI and VAP, respectively) and the total number of QALYs gained (ie, 9.61 and 6.55 from the reduced risk of CLABSI and VAP, respectively). We estimated the total reduction in ICU costs owing to the reduced number of cases of CLABSI and VAP as $174,713.09 and $163,090.54, respectively. Because of the increased postdischarge LY for those in whom infection was averted, the total net present value of postdischarge health care costs increases substantially (ie, $366,901.52 for CLABSI and $201,965.92 for VAP). By combining the ICU-level health benefits and cost differences (both acute and postdischarge) for the CLABSI and the VAP cohorts, and including the ICU-level intervention costs, we estimate ICERs of $14,250.74 per LY gained and $23,277.86 per QALY gained. Table 4 displays the results of the sensitivity analyses. In all cases, the ICERs are <$85,000 per outcome. If the intervention is effective in reducing only 10% of the infections, then the ICER is the highest at just over $83,000 per QALY and $50,000 per LY. When the intervention is applied only to the eldest cohort, those aged 75- 79 years, the resulting ICER is slightly higher than when applied to the younger ICU patients.
DISCUSSION
We used our policy model to assess the long-term cost-effectiveness of a multifaceted infection prevention program in the ICU setting from the societal perspective. We found ongoing investment in infection prevention programs designed to decrease CLABSI and VAP to be a cost-effective strategy. These findings are robust to a number of assumptions. Although many hospitals in the US have already invested in these types of programs, driving the improvement toward national targets, our results serve as a reminder to health administrators and policy makers of the importance of ongoing investment to keep HAI rates down; that is, the welfare improvement implied by the advantageous incremental cost-effectiveness ratio results would be lost if the ongoing investments in prevention policies were suspended.
Other cost-effectiveness analysis models have been developed for specific infection prevention interventions. For example, a decision analytic cost-effectiveness analysis model comparing antiseptic-impregnated catheters to standard catheters has been published. 26 In addition, the use of antimicrobial catheters has been compared with investment in multifaceted infection prevention programs in Australia. 27 Neither of those analyses took the societal perspective or included long-term outcomes and costs attributable to HAIs, however. Unlike those studies, we have developed a longterm cost-effectiveness model that evaluates a composite policy including a variety of elements as represented by the Michigan Keystone ICU Patient Safety Program and uses 5 years of follow-up data to develop long-term projections of health and cost outcomes. This analysis has a number of strengths and limitations. Strengths include the use of long-term societal data, providing a minimum of 5 years of detailed follow-up data on health care outcomes, utilization, and costs. By necessity, however, data were available only for the elderly subjects. Other researchers from a large accountable care organization may be able to use a similar model with data from patients of all ages. The probability of HAI came from data submitted to the CDC. Strengths of these data include the consistent definitions used across multiple hospitals; however, even with the definitions, heterogeneity in the application of the definitions persists. 28 Nonetheless, the NHSN data are the best multisite HAI dataset available. The cost of the intervention was based on implementing a multifaceted infection prevention program nearly a decade ago. Although all cost data were inflated to 2013 dollars, contextual changes, such as the development of new technologies or mandatory reporting of HAIs, may impact workflow and subsequent costs. However, our results were not sensitive to the cost of the intervention. Last, another important limitation of our work is that it is based on estimates from retrospective data and, although we included detailed health status controls in our analyses, our estimates of the long-term effects of infection on health outcomes and health care costs could be biased. We examined the cost-effectiveness of ongoing investments in multifaceted HAI prevention programs in hospital ICUs that have been initiated over the last decade. We believe this costeffectiveness model, which integrates parameter estimates from the literature with empirical estimates of the long-term consequences of HAI, provides a more complete story of the costs and benefits of HAI than has previously been published, and reveals the value of continued efforts to prevent HAI.
Our findings show that the ICERs are small and robust to alternative assumptions indicating that ongoing investments in HAI prevention should be continued. There is no implicit cost-effectiveness threshold; however, it is generally assumed that an ICER <$50,000 is cost-effective and that an ICER >$100,000 is not. 29 The improvements in infection rates brought about by these policies have been substantial, and our long-term modeling of the health and cost-consequences of these infections highlights the value of the interventions and the potential consequences of discontinuing them. Although HAI rates have been reduced dramatically over the last decade, infections remain an ongoing problem, particularly emerging and resistant infections, such as those caused by multiple drug-resistant organisms, including methicillin-resistant Staphylococcus aureus and vancomycin-resistant enterococci, as well as Clostridium difficile diarrhea, which is associated with antibiotic use. The social cost of these infections is high, as demonstrated by our model, and as a consequence, efforts to develop new prevention strategies are warranted.
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